McKesson, private equity firm buy home infusion company, Option Care Health

McKesson Corporation and private equity firm Clayton Dubilier & Rice (CD&R) agreed to acquire Option Care Health, a home infusion company, for $5.8 billion. McKesson will invest $1.4 billion for a 49% stake, with CD&R taking 51%. The deal values Option Care Health at $32.05 per share, a 36% premium over Monday's closing price. Once completed, Option Care Health will become private and delist from Nasdaq.

Original reporting
Published Oct 7, 2026, 3:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 4:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
McKesson, private equity firm buy home infusion company, Option Care Health — source image
Decision brief

The 30-second read

$MCKBullishHigh
01

Why it matters

The acquisition expands McKesson's reach into home‑based therapy, while Option Care shareholders receive a cash premium and the company will be delisted.

02

Market read

A large‑scale M&A event in the healthcare distribution space with immediate price impact on both the acquirer and target.

03

What to watch

Regulatory approval risk and potential antitrust scrutiny could delay or alter deal terms.

Relevance 9/10Novelty 9/10Timing: today

Background

McKesson partners with private‑equity firm CD&R to acquire the nation's largest independent home‑infusion provider, Option Care Health, in a $5.8 billion transaction.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson announced a $5.8 billion acquisition of Option Care Health, taking a 49% stake for $1.4 billion.

Expected impact

likely modest upside as the deal broadens McKesson's service offering and may be viewed as strategic growth.

Evidence & confidence

The acquisition is a large‑scale, first‑report M&A event; investors typically reward strategic expansion.

$OPCHBearishHigh confidence
Context

Option Care Health will be taken private and its Nasdaq listing will be cancelled after the $5.8 billion deal closes.

Expected impact

significant downward pressure as the market prices in the buyout premium and delisting.

Evidence & confidence

Buyout announcements with a premium above market price typically trigger a rapid decline in the target's share price.

Market effects

The deal underscores consolidation in the home infusion and broader drug‑distribution sector, pressuring peers to consider similar strategic moves.

U.S. healthcare services market may see increased M&A activity as large distributors expand into patient‑level care.

Limited to U.S. healthcare and distribution firms; no immediate global macro effect.

Counterpoint

The premium paid may be excessive if integration costs rise, potentially weighing on McKesson's earnings in the near term.

Key entities

  • McKesson Corporation

    U.S. drug wholesaler and distributor.

  • Option Care Health

    Largest independent home‑infusion provider, formerly listed on Nasdaq.

  • Clayton Dubilier & Rice

    Private‑equity firm taking a 51% stake in the deal.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.